Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints Peter Theil head of non-clinical development

He joins the Belgium pharma company from Genentech

Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.

He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.

At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.

UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.

Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.

McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics